A small randomized, placebo-controlled trial using dupilumab (an IL-4/IL-13-blocking antibody) in COVID-19 patients requiring hospitalization demonstrated reduced mortality (13), with follow-up studies showing that patients who received dupilumab had significantly improved lung function scores 1 year post treatment (14). The gene discussed is IL13; the disease is COVID-19.